摘要: |
探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对无法获取PD-L1、TMB、MSI-H等检测的晚期肿瘤患者免疫治疗早期疗效的预测价值。方法:回顾性选取2020年1月- 2021年12月我院收治的接受PD-1单抗治疗的48例晚期肿瘤患者,分析患者年龄、性别、原发肿瘤的部位、免疫治疗的方式及NLR与早期治疗疗效的相关性;通过基线 NLR 预测疾病控制状态的 ROC 曲线以获取 NLR 最佳预测值,根据NLR最佳预测值将患者分为高 NLR组和低 NLR组,分析两组对早期治疗疗效的影响。结果:NLR 的最佳预测值为 3.54。低NLR组客观缓解率(objective response rate,ORR)为20%,高NLR组ORR为7.1%, 低NLR组ORR明显高于高NLR组(P=0.003)。低NLR组疾病控制率(disease control rate,DCR)为85%,高NLR组DCR为35.7%,低NLR组DCR明显高于高NLR组(P=0.001)
结论:晚期肿瘤患者基线NLR对PD-1单抗早期疗效具有潜在预测价值。 |
关键词: 中性粒细胞/淋巴细胞比值 免疫检查点抑制剂 恶性肿瘤 疾病控制率 |
DOI:10.12025/j.issn.1008-6358.2023.20222092 |
分类号:R 730.3 |
基金项目:]国家自然科学(编号:81572796),国家自然科学基金项目(面上项目,重点项目,重大项目) |
|
Predictive Value of Baseline Neutrophil-to-lymphocyte ratio for Early Efficacy in advanced cancer patients receiving immunotherapy |
zhangwenying, huxiaohua, yuanhaihua, wangjiongyi, liufeng
|
The Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Oncology Department
|
Abstract: |
【Abstract】 Objective To explore the predictive value of neutrophil to lymphocyte ratio (NLR) on the therapeutic effects of immunotherapy in advanced cancer patients without PDL1, TMB, MSI-H.
Methods We collected the data of 48 advanced cancer patients treated with PD-1 inhibitors treatment between January 2020 to December 2021. The correlation age, gender, primary tumor type, type of anti-PD-1therapy , NLR and early efficacy was analyzed.The optimal cut-off value of NLR was obtained by ROC curve according to the disease control status. Patients were divided into high-level group and low-level group based on cut-off value of NLR.The early efficacy of NLR and other factors was explored with multivariable regression.
Results The Optimal cut-off value for DCR were 3.54 for NLR.ORR of patients with low NLR group and high NLR group were 20% and 7.1%. DCR of patients with low NLR group and high NLR group were 85% and 35.7%.ORR and DCR of low NLR group were higher than high NLR group (P=0.003 and P=0.001).
Conclusion Baseline NLR has potential predictive value for early efficacy in advanced cancer patients treated with PD-1 monoclonal antibody therapy. |
Key words: Neutrophil-to-lymphocyte ratio (NLR), Immune checkpoint inhibitors malignant tumor disease control rate(DCR) |